The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Bristol Myers Squibb Ireland Unlimited competitive analysis

Loading summary...

Latest patents of Bristol Myers Squibb Ireland Unlimited opposed by its competitors

Explore Bristol Myers Squibb Ireland Unlimited's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP3246021
Nov 13, 2019Apixaban Formulations12
EP3251660
Oct 16, 2019Apixaban Formulations10
EP3257500
Oct 16, 2019Apixaban Formulations10
EP3017811
Dec 5, 2018Apixaban Formulations10
EP3054926
Jul 25, 2018Hiv Treatment Formulation Of Atazanavir And Cobicistat1

Latest PTAB cases involving Bristol Myers Squibb Ireland Unlimited

Discover the latest PTAB cases involving Bristol Myers Squibb Ireland Unlimited, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Bristol Myers Squibb Ireland Unlimited with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BRISTOL MYERS SQUIBB IRELAND UNLIMITED - 43 - -
GENERICS UK214 - - -
INTAS PHARMACEUTICALS1643 -
TEVA PHARMACEUTICALS20916 - 12